Finerenone: A Potential Treatment for Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus-Reference-Cited by-同舟云学术

Finerenone: A Potential Treatment for Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus

Published:2021 Issue:2 Volume:17 Page:84
ISSN:1758-3772
Container-title:European Endocrinology
language:en
Short-container-title:

Author:

D’Marco Luis,Puchades María Jesús,Gandía Lorena,Forquet Claudia,Giménez-Civera Elena,Panizo Nayara,Reque Javier,Juan-García Isabel,Bermúdez Valmore,Gorriz José Luis, , , , , , , , , , , , ,

Abstract

Funder

This article is published under the Creative Commons Attribution Non-commercial License.

Publisher

Touch Medical Media, Ltd.

Subject

Endocrine and Autonomic Systems,Endocrinology,Endocrinology, Diabetes and Metabolism

Reference31 articles.

1. Rowley WR, Bezold C, Arikan Y, et al. Diabetes 2030: Insights from yesterday, today, and future trends. Popul Health Manag. 2017;20:6–12.

2. Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843.

3. Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2020;63:221-8. Correction in: Diabetologia. 2020;63:1667.

4. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295–306.

5. Agarwal R, Kolkhof P, Bakris G, et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J. 2021;42:152–61.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The significance of finerenone as a novel therapeutic option in diabetic kidney disease: a scoping review with emphasis on cardiorenal outcomes of the finerenone phase 3 trials;Frontiers in Medicine;2024-06-14

2. Overview of the safety, efficiency, and potential mechanisms of finerenone for diabetic kidney diseases;Frontiers in Endocrinology;2023-12-20

3. Cardiometabolic risk management: insights from a European Society of Cardiology Cardiovascular Round Table;European Heart Journal;2023-07-14

4. Cardiorenal benefits of finerenone: protecting kidney and heart;Annals of Medicine;2023-01-31

5. Research Progress in Finerenone in Cardiovascular Diseases;Cardiovascular Innovations and Applications;2023